Sun Pharma Sees 26% Rise in Q4 Net Profit to Rs 2,714 Crore

Sun Pharmaceutical Industries Reports Strong Growth in Fourth Quarter FY26

Sun Pharmaceutical Industries, India's largest pharmaceutical company, reported a 26.2 percent year-on-year rise in consolidated net profit for the fourth quarter of FY26 at Rs 2,714 crore. This growth was driven by strong performance in its India business and innovative medicines portfolio. The company's board has proposed a final dividend of Rs 5 per equity share for FY26.

Consolidated revenue from operations increased 13.6 percent on-year to Rs 14,559.8 crore during the January-March quarter. The total dividend for FY26 stands at Rs 16 per share, unchanged from FY25. This includes an interim dividend of Rs 11 per share already paid during the year.

Sun Pharma's India formulations business remained its largest market, with sales rising 14.8 percent year-on-year to Rs 4,835.9 crore in the quarter. The India business contributed 33.2 percent of consolidated sales. For the full year FY26, India formulation sales grew 14 percent to Rs 19,290.4 crore.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

The company said it retained its position as India's largest pharmaceutical company. According to the Pharmarack MAT March 2026 report, Sun Pharma's market share increased to 8.4 percent from 8.1 percent a year earlier. The company launched 11 new products during the quarter and 37 products during FY26.

In the United States, Sun Pharma's formulation sales stood at $459 million, down 1.1 percent year-on-year, as growth in innovative medicines offset weakness in the generics business. The US market accounted for about 28.8 percent of consolidated sales during the quarter. Full-year US formulation sales were $1.90 billion.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

The company's innovative medicines business continued to deliver strong growth. Global innovative medicines sales rose 20.1 percent year-on-year to $354 million and contributed 22.2 percent of consolidated revenue during the quarter.

On a geographic basis, India contributed 33 percent of fourth-quarter sales, followed by the US at 29 percent, emerging markets at 19 percent, rest of the world markets at 14 percent and API and other businesses at 5 percent.

Sun Pharma reported EBITDA of Rs 3,954.2 crore for the quarter, up 6.4 percent year-on-year, with EBITDA margin at 27.1 percent. Research and development expenditure stood at Rs 975.7 crore, representing 6.7 percent of sales.

For FY26, the company reported overall sales growth of 11.9 percent, while EBITDA margin stood at 30.3 percent.

Managing Director Dilip Shanghvi commented on the performance, stating that the company delivered strong growth during the quarter, driven by its diversified business and continued momentum in innovative medicines, while maintaining investments in research and development.